PDC activity levels were also shown to be significantly lower in patients with clinical liver cancer compared to healthy subjects (Fig. 3C), an observation that could be attributed to high levels of PDHX Lys 488 acetylation in patients (Fig. 1D–F). This evidence concerns the gene PDHX and liver cancer.